Vol 55, No 3 (2021)
Review Article
Published online: 2021-02-04

open access

Page views 2016
Article views/downloads 1218
Get Citation

Connect on Social Media

Connect on Social Media

Genetics of Parkinson’s disease in the Polish population

Łukasz M. Milanowski123, Owen A. Ross2, Andrzej Friedman3, Dorota Hoffman-Zacharska4, Paulina Gorka-Skoczylas4, Marta Jurek4, Dariusz Koziorowski3, Zbigniew K. Wszolek1
Pubmed: 33539026
Neurol Neurochir Pol 2021;55(3):241-252.


Introduction. Genetic forms of Parkinson’s disease (PD) often cluster in different ethnic groups and may present with recognisable unique clinical manifestations. Our aim was to summarise the current state of knowledge regarding the genetic causes of PD and describe the first Polish patient with SNCA duplication.

Methodology. We searched the electronic database, PubMed, for studies between January 1995 and June 2020 that evaluated genetics in Polish patients with PD, using the search terms ‘Parkinson’s disease, ‘Polish’, ‘genetics’, ‘mutations’, and ‘variants’.

Results. In total, 73 publications were included in the review; 11 genes responsible for monogenic forms and 19 risk factor genes have been analysed in the Polish population. Pathogenic variants were reported in four monogenic genes (LRRK2, PRKN, PINK1, and SNCA). Eight genes were associated with PD risk in the Polish population (GBA, TFAM, NFE2L2, MMP12, HLA-DRA, COMT, MAOB, and DBH). Multiplex ligation-dependent probe amplification and Sanger sequencing in PRKN, PINK1, DJ1, LRRK2, and SNCA revealed SNCA duplication in a 43-year-old Polish patient with PD examined by movement disorder specialists.

Conclusion. Only a limited number of positive results have been reported in genes previously associated with PD in the Polish population. In the era of personalised medicine, it is important to report on genetic findings in specific populations.

Article available in PDF format

View PDF Download PDF file


  1. Balestrino R, Schapira A. Parkinson disease. European Journal of Neurology. 2019; 27(1): 27–42.
  2. Yoon WT. Comparison of dystonia between Parkinson's disease and atypical parkinsonism: The clinical usefulness of dystonia distribution and characteristics in the differential diagnosis of parkinsonism. Neurol Neurochir Pol. 2018; 52(1): 48–53.
  3. Siuda J, Boczarska-Jedynak M, Budrewicz S, et al. Validation of the Polish version of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS). Neurol Neurochir Pol. 2020; 54(5): 416–425.
  4. Tipton PW, Uitti RJ, Cheshire WP. 'Falling off' the dopamine wagon. Neurol Neurochir Pol. 2019; 53(5): 390–391.
  5. Barc K, Kuźma-Kozakiewicz M. Positron emission tomography neuroimaging in neurodegenerative diseases: Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. Neurol Neurochir Pol. 2019; 53(2): 99–112.
  6. Gajos A, Dąbrowski J, Bieńkiewicz M, et al. Should non-movement specialists refer patients for SPECT-DaTSCAN? Neurol Neurochir Pol. 2019; 53(2): 138–143.
  7. Pringsheim T, Jette N, Frolkis A, et al. The prevalence of Parkinson's disease: a systematic review and meta-analysis. Mov Disord. 2014; 29(13): 1583–1590.
  8. Chan JCN, Malik V, Jia W, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA. 2009; 301(20): 2129–2140.
  9. Jost WH, Altmann C, Fiesel T, et al. Influence of levodopa on orthostatic hypotension in Parkinson's Disease. Neurol Neurochir Pol. 2020; 54(2): 200–203.
  10. Sauerbier A, Aris A, Lim EeW, et al. Impact of ethnicity on the natural history of Parkinson disease. Med J Aust. 2018; 208(9): 410–414.
  11. Deutschländer AB. Treatment with istradefylline for postural abnormalities in Parkinson's disease. Neurol Neurochir Pol. 2019; 53(4): 239–241.
  12. Szlufik S, Przybyszewski A, Dutkiewicz J, et al. Evaluating reflexive saccades and UDPRS as markers of Deep Brain Stimulation and Best Medical Treatment improvements in Parkinson's disease patients: a prospective controlled study. Neurol Neurochir Pol. 2019; 53(5): 341–347.
  13. Nalls MA, Blauwendraat C, Vallerga CL, et al. 23andMe Research Team, System Genomics of Parkinson's Disease Consortium, International Parkinson's Disease Genomics Consortium. Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 2019; 18(12): 1091–1102.
  14. GBD 2016 Neurology Collaborators, GBD 2016 Parkinson's Disease Collaborators. Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018; 17(11): 939–953.
  15. Domingo A, Klein C. Genetics of Parkinson disease. Neurogenetics, Part I. 2018: 211–227.
  16. Ambroziak W, Koziorowski D, Duszyc K, et al. Genomic instability in the PARK2 locus is associated with Parkinson's disease. J Appl Genet. 2015; 56(4): 451–461.
  17. Ando M, Fiesel FC, Hudec R, et al. The PINK1 p.I368N mutation affects protein stability and ubiquitin kinase activity. Mol Neurodegener. 2017; 12(1): 32.
  18. Bialecka M, Hui S, Klodowska-Duda G, et al. Analysis of LRRK2 G2019S and I2020T mutations in Parkinson's disease. Neuroscience Letters. 2005; 390(1): 1–3.
  19. Chartier-Harlin MC, Dachsel JC, Vilariño-Güell C, et al. Translation initiator EIF4G1 mutations in familial Parkinson disease. Am J Hum Genet. 2011; 89(3): 398–406.
  20. Gaweda-Walerych K, Safranow K, Jasinska-Myga B, et al. PARK2 variability in Polish Parkinson's disease patients--interaction with mitochondrial haplogroups. Parkinsonism Relat Disord. 2012; 18(5): 520–524.
  21. Hoffman-Zacharska D, Koziorowski D, Ross OA, et al. Novel A18T and pA29S substitutions in α-synuclein may be associated with sporadic Parkinson's disease. Parkinsonism Relat Disord. 2013; 19(11): 1057–1060.
  22. Kachergus J, Mata IF, Hulihan M, et al. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am J Hum Genet. 2005; 76(4): 672–680.
  23. Koziorowski D, Hoffman-Zacharska D, Sławek J, et al. Incidence of mutations in the PARK2, PINK1, PARK7 genes in Polish early-onset Parkinson disease patients. Neurol Neurochir Pol. 2013; 47(4): 319–324.
  24. Koziorowski D, Hoffman-Zacharska D, Sławek J, et al. Low frequency of the PARK2 gene mutations in Polish patients with the early-onset form of Parkinson disease. Parkinsonism Relat Disord. 2010; 16(2): 136–138.
  25. Lorenzo-Betancor O, Ogaki K, Soto-Ortolaza AI, et al. DNAJC13 p.Asn855Ser mutation screening in Parkinson's disease and pathologically confirmed Lewy body disease patients. Eur J Neurol. 2015; 22(9): 1323–1325.
  26. Ogaki K, Koga S, Heckman MG, et al. Mitochondrial targeting sequence variants of the CHCHD2 gene are a risk for Lewy body disorders. Neurology. 2015; 85(23): 2016–2025.
  27. Puschmann A, Fiesel FC, Caulfield TR, et al. Heterozygous PINK1 p.G411S increases risk of Parkinson's disease via a dominant-negative mechanism. Brain. 2017; 140(1): 98–117.
  28. Ross OA, Soto AI, Vilariño-Güell C, et al. Genetic variation of Omi/HtrA2 and Parkinson's disease. Parkinsonism Relat Disord. 2008; 14(7): 539–543.
  29. Siuda J, Jasinska-Myga B, Boczarska-Jedynak M, et al. Early-onset Parkinson's disease due to PINK1 p.Q456X mutation--clinical and functional study. Parkinsonism Relat Disord. 2014; 20(11): 1274–1278.
  30. Vilariño-Güell C, Wider C, Ross OA, et al. VPS35 mutations in Parkinson disease. Am J Hum Genet. 2011; 89(1): 162–167.
  31. Potulska-Chromik A, Hoffman-Zacharska D, Łukawska M, et al. Dopa-responsive dystonia or early-onset Parkinson disease - Genotype-phenotype correlation. Neurol Neurochir Pol. 2017; 51(1): 1–6.
  32. Schrag A, Schott JM. Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism. Lancet Neurol. 2006; 5(4): 355–363.
  33. Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 1998; 392(6676): 605–608.
  34. Kasten M, Hartmann C, Hampf J, et al. Genotype-Phenotype Relations for the Parkinson's Disease Genes Parkin, PINK1, DJ1: MDSGene Systematic Review. Mov Disord. 2018; 33(5): 730–741.
  35. Valente EM, Abou-Sleiman PM, Caputo V, et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science. 2004; 304(5674): 1158–1160.
  36. Watzlawik JO, Hou Xu, Fricova D, et al. Sensitive ELISA-based detection method for the mitophagy marker p-S65-Ub in human cells, autopsy brain, and blood samples. Autophagy. 2020 [Epub ahead of print]: 1–16.
  37. Bonifati V, Rizzu P, Squitieri F, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science. 2003; 299(5604): 256–259.
  38. Moore DJ, Zhang Li, Dawson TM, et al. A missense mutation (L166P) in DJ-1, linked to familial Parkinson's disease, confers reduced protein stability and impairs homo-oligomerization. J Neurochem. 2003; 87(6): 1558–1567.
  39. Funayama M, Hasegawa K, Ohta E, et al. An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. Ann Neurol. 2005; 57(6): 918–921.
  40. Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 2004; 44(4): 601–607.
  41. Lesage S, Dürr A, Tazir M, et al. French Parkinson's Disease Genetics Study Group. LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N Engl J Med. 2006; 354(4): 422–423.
  42. Ozelius LJ, Senthil G, Saunders-Pullman R, et al. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N Engl J Med. 2006; 354(4): 424–425.
  43. Lesage S, Leutenegger AL, Ibanez P, et al. French Parkinson's Disease Genetics Study Group. LRRK2 haplotype analyses in European and North African families with Parkinson disease: a common founder for the G2019S mutation dating from the 13th century. Am J Hum Genet. 2005; 77(2): 330–332.
  44. Zimprich A, Benet-Pagès A, Struhal W, et al. A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am J Hum Genet. 2011; 89(1): 168–175.
  45. Shannon B, Soto-Ortolaza A, Rayaprolu S, et al. Genetic variation of the retromer subunits VPS26A/B-VPS29 in Parkinson's disease. Neurobiol Aging. 2014; 35(8): 1958.e1–1958.e2.
  46. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997; 276(5321): 2045–2047.
  47. Muenter MD, Forno LS, Hornykiewicz O, et al. Hereditary form of parkinsonism--dementia. Ann Neurol. 1998; 43(6): 768–781.
  48. Book A, Guella I, Candido T, et al. SNCA Multiplication Investigators of the GEoPD Consortium. A Meta-Analysis of α-Synuclein Multiplication in Familial Parkinsonism. Front Neurol. 2018; 9: 1021.
  49. Ibáñez P, Lesage S, Janin S, et al. French Parkinson's Disease Genetics Study Group. Alpha-synuclein gene rearrangements in dominantly inherited parkinsonism: frequency, phenotype, and mechanisms. Arch Neurol. 2009; 66(1): 102–108.
  50. Fan TS, Lin HI, Lin CH, et al. Lack of CHCHD2 mutations in Parkinson's disease in a Taiwanese population. Neurobiol Aging. 2016; 38: 218.e1–218.e2.
  51. Vilariño-Güell C, Rajput A, Milnerwood AJ, et al. DNAJC13 mutations in Parkinson disease. Hum Mol Genet. 2014; 23(7): 1794–1801.
  52. Huttenlocher J, Krüger R, Capetian P, et al. EIF4G1is neither a strong nor a common risk factor for Parkinson's disease: evidence from large European cohorts: Table1. Journal of Medical Genetics. 2014; 52(1): 37–41.
  53. Strauss KM, Martins LM, Plun-Favreau H, et al. Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. Hum Mol Genet. 2005; 14(15): 2099–2111.
  54. Soto-Ortolaza AI, Ross OA. Genetic susceptibility variants in parkinsonism. Parkinsonism Relat Disord. 2016; 22 Suppl 1: S7–11.
  55. Kim MS, Patel KP, Teng AK, et al. Genetic disease risks can be misestimated across global populations. Genome Biol. 2018; 19(1): 179.
  56. Zhao F, Bi L, Wang W, et al. Mutations of glucocerebrosidase gene and susceptibility to Parkinson's disease: An updated meta-analysis in a European population. Neuroscience. 2016; 320: 239–246.
  57. Jamrozik Z, Lugowska A, Kosiorowski D. Beta-Glucocerebrosidase Gene Mutations P.Asn409Ser and P.Leu483Pro in Polish Patients with Parkinson's Disease. Journal of Neurology and Neuroscience. 2015; 06(04).
  58. Malec-Litwinowicz M, Plewka A, Plewka D, et al. The relation between plasma α-synuclein level and clinical symptoms or signs of Parkinson's disease. Neurol Neurochir Pol. 2018; 52(2): 243–251.
  59. Iwaki H, Blauwendraat C, Leonard HL, et al. International Parkinson's Disease Genomics Consortium. Genomewide association study of Parkinson's disease clinical biomarkers in 12 longitudinal patients' cohorts. Mov Disord. 2019; 34(12): 1839–1850.
  60. Pierzchlińska A, Białecka M, Kurzawski M, et al. The impact of Apolipoprotein E alleles on cognitive performance in patients with Parkinson's disease. Neurol Neurochir Pol. 2018; 52(4): 477–482.
  61. Białecka M, Droździk M, Honczarenko K, et al. Catechol-O-methyltransferase and monoamine oxidase B genes and susceptibility to sporadic Parkinson's disease in a Polish population. Eur Neurol. 2005; 53(2): 68–73.
  62. Białecka M, Droździk M, Kłodowska-Duda G, et al. The effect of monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinson's disease. Acta Neurol Scand. 2004; 110(4): 260–266.
  63. Bialecka M, Klodowska-Duda G, Kurzawski M, et al. Interleukin-10 gene polymorphism in Parkinson's disease patients. Arch Med Res. 2007; 38(8): 858–863.
  64. Bialecka M, Kurzawski M, Klodowska-Duda G, et al. Polymorphism in semaphorin 5A (Sema5A) gene is not a marker of Parkinson's disease risk. Neurosci Lett. 2006; 399(1-2): 121–123.
  65. Białecka M, Kurzawski M, Vlaykova T, et al. Effects of common functional MMP12 gene polymorphisms on PD in a Polish population. Neurol Neurochir Pol. 2017; 51(5): 347–353.
  66. Dachsel JC, Wider C, Vilariño-Güell C, et al. Death-associated protein kinase 1 variation and Parkinson's disease. Eur J Neurol. 2011; 18(8): 1090–1093.
  67. Gaweda-Walerych K, Safranow K, Maruszak A, et al. Mitochondrial transcription factor A variants and the risk of Parkinson's disease. Neurosci Lett. 2010; 469(1): 24–29.
  68. Jasinska-Myga B, Wider C, Opala G, et al. GRN 3'UTR+78 C>T is not associated with risk for Parkinson's disease. Eur J Neurol. 2009; 16(8): 909–911.
  69. Labbé C, Ogaki K, Lorenzo-Betancor O, et al. Role for the microtubule-associated protein tau variant p.A152T in risk of α-synucleinopathies. Neurology. 2015; 85(19): 1680–1686.
  70. Müller-Nedebock AC, Brennan RR, Venter M, et al. The unresolved role of mitochondrial DNA in Parkinson's disease: An overview of published studies, their limitations, and future prospects. Neurochem Int. 2019; 129: 104495.
  71. Peplonska B, Safranow K, Gaweda-Walerych K, et al. TOMM40 and APOE common genetic variants are not Parkinson's disease risk factors. Neurobiol Aging. 2013; 34(8): 2078.e1–2078.e2.
  72. Pepłońska B, Zekanowski C, Religa D, et al. Strong association between Saitohin gene polymorphism and tau haplotype in the Polish population. Neurosci Lett. 2003; 348(3): 163–166.
  73. Puschmann A, Verbeeck C, Heckman MG, et al. Human leukocyte antigen variation and Parkinson's disease. Parkinsonism Relat Disord. 2011; 17(5): 376–378.
  74. Rayaprolu S, Mullen B, Baker M, et al. TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson's disease. Mol Neurodegener. 2013; 8: 19.
  75. Ross OA, Heckman MG, Soto AI, et al. Dopamine beta-hydroxylase -1021C>T association and Parkinson's disease. Parkinsonism Relat Disord. 2008; 14(7): 544–547.
  76. Soto-Ortolaza AI, Behrouz B, Wider C, et al. Calbindin-1 association and Parkinson's disease. Eur J Neurol. 2010; 17(2): 208–211.
  77. Tan EK, Drozdzik M, Bialecka M, et al. Analysis of MDR1 haplotypes in Parkinson's disease in a white population. Neurosci Lett. 2004; 372(3): 240–244.
  78. von Otter M, Landgren S, Nilsson S, et al. Association of Nrf2-encoding NFE2L2 haplotypes with Parkinson's disease. BMC Med Genet. 2010; 11: 36.
  79. Truban D, Hou Xu, Caulfield TR, et al. PINK1, Parkin, and Mitochondrial Quality Control: What can we Learn about Parkinson's Disease Pathobiology? J Parkinsons Dis. 2017; 7(1): 13–29.
  80. Noack H, Bednarek T, Heidler J, et al. TFAM-dependent and independent dynamics of mtDNA levels in C2C12 myoblasts caused by redox stress. Biochim Biophys Acta. 2006; 1760(2): 141–150.
  81. Gaweda-Walerych K, Maruszak A, Safranow K, et al. Mitochondrial DNA haplogroups and subhaplogroups are associated with Parkinson's disease risk in a Polish PD cohort. J Neural Transm (Vienna). 2008; 115(11): 1521–1526.
  82. Liu Y, Zhang M, Hao W, et al. Matrix metalloproteinase-12 contributes to neuroinflammation in the aged brain. Neurobiol Aging. 2013; 34(4): 1231–1239.
  83. Michałowska M, Chalimoniuk M, Jówko E, et al. Gene polymorphisms and motor levodopa-induced complications in Parkinson's disease. Brain Behav. 2020; 10(3): e01537.
  84. Labbé C, Ogaki K, Lorenzo-Betancor O, et al. Exonic Re-Sequencing of the Chromosome 2q24.3 Parkinson's Disease Locus. PLoS One. 2015; 10(6): e0128586.
  85. Mizuta I, Tsunoda T, Satake W, et al. Calbindin 1, fibroblast growth factor 20, and alpha-synuclein in sporadic Parkinson's disease. Hum Genet. 2008; 124(1): 89–94.
  86. Krygowska-Wajs A, Kachergus JM, Hulihan MM, et al. Clinical and genetic evaluation of 8 Polish families with levodopa-responsive parkinsonism. J Neural Transm (Vienna). 2005; 112(11): 1487–1502.
  87. Krygowska-Wajs A, Hussey JM, Hulihan M, et al. Two large Polish kindreds with levodopa-responsive Parkinsonism not linked to known Parkinsonian genes and loci. Parkinsonism Relat Disord. 2003; 9(4): 193–200.
  88. Figura M, Friedman A. In search of Parkinson's disease biomarkers - is the answer in our mouths? A systematic review of the literature on salivary biomarkers of Parkinson's disease. Neurol Neurochir Pol. 2020; 54(1): 14–20.
  89. Schneider SA, Alcalay RN. Precision medicine in Parkinson's disease: emerging treatments for genetic Parkinson's disease. J Neurol. 2020; 267(3): 860–869.
  90. Fiandaca MS, Lonser RR, Elder JB, et al. Advancing gene therapies, methods, and technologies for Parkinson's Disease and other neurological disorders. Neurol Neurochir Pol. 2020; 54(3): 220–231.
  91. Padmanabhan S, Polinski NK, Menalled LB, et al. The Michael J. Fox Foundation for Parkinson's Research Strategy to Advance Therapeutic Development of PINK1 and Parkin. Biomolecules. 2019; 9(8).

Neurologia i Neurochirurgia Polska